this week we've had RFD4-Proteina @UWproteindesign, Omnii-1 @RadicalNumerics, scorpion minibinders @AnthropicAI, lab digital twins @GoogleResearch... this is too much, guys, I cannot read all these blog posts let alone these papers

This guy reads The Inner Game of Tennis

One of the best concise explainations of synthetic biology from @PeterDiamandis If this is interesting to you, I hope you'll join us at @SynBioBeta 2027

Congratulations to @lifeext @KEricDrexler for having co-founded an organization that was unusually early, often right, and always prescient when it comes to envisioning and building flourishing futures defined by the interplay of strong technology - from molecular nanotechnology, longevity escape velocity, sovereign AI, to neurotechnology. You were the reason I packed up my life a decade ago to move to the Bay and I've been grateful for that every day since.

If you work in biomanufacturing in the Bay Area, the @agilebiofoundry Fall 2026 Industry Day in Berkeley on October 26 is a must attend. Registration closes this Monday, October 12. ABF is the DOE national lab consortium building tools, processes, and partnerships for industrial biomanufacturing. Industry Day is where companies bring real scale-up problems and the labs show what they can do about them. Industry perspective talks from: - Magdalena Stoeva of @powbio - @markvanzee of @sakubiosciences - Michael Wang of @ZymoChem The day also includes: - Lightning talks on synbio, AI, automation, and scale-up - Panels on AI and automation, host onboarding, and metabolic intermediates - The launch of the ABF Industry Accelerator - 1:1 meetings with ABF scientists - An optional tour of a local scale-up facility Hotel Shattuck Plaza, 8 AM to 5 PM. Some sessions stream virtually, but the roundtables and 1:1s are the reason to show up in person. Register: agilebiofoundry.org/fall-202…

Excited to announce two of our keynote speakers for @SynBioBeta 2027: @geochurch, founder of more than 50 companies in the synthetic biology space, and @alexrives, who runs @biohub. Church's list includes @editasmed, Nebula Genomics, Veritas Genetics, GRO Biosciences, Rejuvenate Bio, @ManifoldBio, Gen9, Form Bio, and @itiscolossal, now at a $10.3B valuation. He developed the first direct genome sequencing method, helped initiate the Human Genome Project, started @PGorg in 2005, and runs the synthetic biology platform at @WyssInstitute. He teaches at @Harvard and @MIT. This year alone, Colossal partnered with US Fish and Wildlife to biobank every endangered species and published a gene drive plan to eliminate the New World screwworm in the US. Rives founded and led the ESM project at Meta's FAIR lab, which built the first large transformer language models for proteins, then spun @EvoscaleAI out with his former Meta colleagues after Meta shut the team down in 2023. That company raised $142M from Nat Friedman, Daniel Gross, @Lux_Capital, Amazon, and NVIDIA's NVentures and shipped ESM3, a 98B parameter model trained on 2.78B protein sequences that reasons over sequence, structure, and function at once. CZI acquired EvolutionaryScale in November 2025 and folded it into Biohub, with Rives as head of science. In May, that team released ESMFold2 and the ESM Atlas, mapping 6.8B sequences and 1.1B predicted structures to protein function. A month later they reported binder hits against five cancer and immune targets. The models are distributed through AWS Bio Discovery and SandboxAQ. He is also core faculty at @BroadInstitute and an assistant professor in EECS at @MIT. Two people making the same bet from opposite ends of the field. Rives came out of an AI lab and treats sequence, structure, and function as a single modeling problem, which is what moves a team from a disease target to a candidate binder in months instead of years. Church has been on the discovery side since 1984, when he published the first direct genome sequencing method, and has spent the four decades since turning academic work into CRISPR editing, recoded genomes, and a company list longer than most venture portfolios. That is the pairing we are programming around for 2027: the frontier AI labs that have moved inside biology, and the academic lineage that built the tools they train on. And this is just the start. We have an incredibly exciting speaker list coming together, and we will be announcing names over the coming months. Keep an eye out. SynBioBeta 2027 is May 3 to 6 at the San Jose McEnery Convention Center, and it is set to be our best conference yet. syntheticbiologysummit.com/?…

So glad to see important projects for Humanity being mapped out in ways that enable distributed collaboration and contribution.

?¿? #BioTwitter: Why aren't governments $incentivizing$ would-be mothers to use IVF for monozygotic twins? The ultimate natural experiment...built-in control group to decode nature vs. nurture and diseases. Investing in twin births is investing in medical breakthroughs. 🧬

Build the Fun version of this...

The LLMs are winning Fields medals — usually the domain of formally educated PhD mathematicians who train for years and reason on hard problems with every ounce of brilliance they have. Yes, training datasets matter. Yes, causal perturbations matter. Yes, depth of phenotyping matters. Yes, there is bias in published literature. Yes to all the critiques :) But maybe — just maybe — we should suspend our disbelief in the biotech community just a little bit and make sure we are taking the LLM capabilities for a real spin in every way that we possibly can…

How's everyone's fast-takeoff planning going?

The Biotech Barbell Club is hosting our next group lifting workout in San Diego at @IAmBiotech Conference on Sunday June 21st . Join us! It's great to lift with biotech professionals from all over the world before the biggest conferences of the year. luma.com/wxkt4j40

Anthropic Says Life Sciences Is Its Biggest Bet After Code. Eric Kauderer-Abrams started @AnthropicAI 's life sciences division ten months ago. He took on the stage at @SynBioBeta with Marc Tessier-Lavigne from @Xaira_Thera , and what caught my attention was how plainly Eric stated the following: "The greatest opportunity to have a beneficial, scaled impact with everything that's happening in frontier AI is in the life sciences." After coding, it's their biggest investment area. They've been training Claude on bioinformatics, chemistry, molecule design, structural biology, clinical regulatory. Their models went from mediocre in life sciences to roughly PhD level across most domains in under a year. That's a steep curve. But what I found more telling than the benchmarks was the infrastructure they're building around it. Wet labs for basic research so their own scientists hit the walls firsthand. An acquisition of Coefficient Bio (acquired by Anthropic) to teach @claudeai how to think like a biotech program manager, not just a bench scientist. The gap between "Claude can answer a biology question" and "Claude can help you run a drug program" is enormous, and they're clearly aware of it. Marc mentioned that 90% of drugs fail in the clinic. Two-thirds of those failures aren't bad science, but patient matching. You have a good target, a good drug, and you can't find who will respond. That's the problem both of them kept circling back to, and it's where causal AI models trained on real perturbation data might actually move the needle. Marc said nobody's pushing a button for a development candidate anytime soon. But Anthropic went from $1B to $30B in revenue in sixteen months. That kind of resource behind this kind of focus is new. It's fun to think of what R&D can look like in the next few months! #SynBioBeta2026 #SyntheticBiology #Biotech #AIxBio

Excited to integrate @Ginkgo Cloud Lab into Microsoft Discovery! Assuming the frontier model companies let us ask questions about biology🙃 then will need easy interfaces to ordering lab work -- awesome to be building that w/ the team at @Microsoft! techcommunity.microsoft.com/…

New Science Blog: Why has AI advanced faster in coding than in biology? To agents, bio databases are like cities built before cars—maddening to drive in because they're designed for different traffic. How do we build infrastructure agents can use? anthropic.com/research/agent…

NeuroAge Therapeutics featured in Stat News article on Vitalist Bay. Body scans, blood tests, and bodyoids Most people in the longevity community are focused on preserving their health as long as they can — either to make it to the current outer limits of longevity, about 120 robust years or so, or to last long enough that science achieves what’s known as longevity escape velocity, where advancements keep piling up so that there’s no limit on how long life might last... I stopped to talk with NeuroAge founder and CEO Christin Glorioso, a neuroscientist who was inspired to start the company because her grandmother developed Alzheimer’s. (Peterson’s mother had Alzheimer’s too; it was a common thread among attendees.) Using brain MRIs and blood biomarkers, the NeuroAge tests aim to help give people the tools to prevent dementia with both data and recommended interventions. Glorioso said she’d been able to grow her own hippocampus 1.5%, which she credited to some combination of hormone replacement therapy, better sleep, statins, VO2 max training, Norwegian 4X4 high-intensity interval training, and GLP-1 drugs. Beside her was Stephen Hubbard, a buff director of business development at NeuroAge and leader of the Biotech Barbell Club, who was also leading weightlifting sessions elsewhere on the Lighthaven premises. I asked about the political breakdown of the longevity crowd, having just wandered away from a speech by the grandson of economist Milton Friedman about seasteading and charter cities. There were a fair amount of libertarians and some fans of the Make America Healthy Again movement, Hubbard said, though he did not count himself among their ranks. “Can’t we have sanity around vaccines and pullups?” he said. Whatever one’s goal, it was clear from the companies with booths set up at Vitalist Bay that there are ample opportunities in the business of longevity. Most of these were focused on personalized medicine. Along with Rythm ($79 a month), I spotted biological age testing company TruDiagnostic ($499 for a one-time test), brain age testing company NeuroAge ($1,398 for the most popular plan), and sleep testing company Empower Sleep ($1,200 for the basic plan)... What motivated many people at Vitalist Bay was not so much the chance to live forever, it seemed, but more freedom to enjoy all the different things that make them feel happy and fulfilled in abundance. For that, the typical human lifespan simply isn’t long enough. One ebullient woman at a weight-lifting session predicted she’d live about 5,000 years. I asked what she’d do with all those bonus millennia. “I don’t know,” she said. “But I’d like to find out.” Full article: statnews.com/2026/05/27/long…

Looking forward to seeing some folks at the NeuroAge Therapeutics booth at Vitalist Bay tomorrow in Berkeley! Come test your reaction time. Faster reaction time predicts sharper brain function and less future dementia risk- and you can train it! So where you are now is movable. with @StephenGHubbard

Sidewynder is cool tech!

The most facinating part of the @SynBioBeta confrence this year has been having big AI players (@AnthropicAI, @OpenAI , @GoogleDeepMind) talking openly about their investments in accelerating important bioscience projects.

Hey Biotech Twitter - who has some @amyris #Purecane sweetener and can bring it to @SynBioBeta? I need if for... and experiment...